Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Plays Up Its In-house Potential, Avoids M&A Talk

Executive Summary

Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.

You may also be interested in...



Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year. 

Pfizer Remains Flexible On Consumer Health In Restructuring

The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.

Pfizer Remains Flexible On Consumer Health In Restructuring

The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel